At a signing ceremony for a global supply chain strategy partnership marking the 30th anniversary between GC Biopharma and Cytiva, Shin Woong, head of operations at GC Biopharma (right), and Kim Sung-pil, president of Cytiva Korea (left), pose for a commemorative photo./Courtesy of GC Biopharma

GC Biopharma(006280) will strengthen the supply chain for key consumables needed to produce biopharmaceuticals.

GC Biopharma said on the 16th that it signed a memorandum of understanding (MOU) with global life sciences corporations Cytiva to ensure a stable supply of key consumables for biopharmaceutical production and to cooperate on process technology.

The two companies agreed to establish a system to prioritize the supply of key consumables, such as virus removal filters needed to produce the blood product "Aliglo." The plan is to minimize production disruptions caused by fluctuations in the global supply chain.

They also agreed to expand support and training for mRNA and cell and gene therapy (CGT) production processes by using Cytiva's APAC Fast Trak Center in Songdo, Incheon.

GC Biopharma and Cytiva have been working together since 1996.

※ This article has been translated by AI. Share your feedback here.